NCT05338762 is a clinical trial in SARS-CoV2 Infection, sponsored by MiCo BioMed Co., Ltd..

Who is sponsoring NCT05338762?

NCT05338762 is sponsored by MiCo BioMed Co., Ltd..

What condition does NCT05338762 study?

NCT05338762 studies SARS-CoV2 Infection.

Is NCT05338762 still recruiting?

NCT05338762 is currently completed. Last updated 11 August 2022.

Last reviewed 2022-08-11 · How we verify

NCT05338762

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

Completed Last updated 11 August 2022

What this trial tests

trial in SARS-CoV2 Infection in 218 participants. Completed in 3 August 2022.

Timeline

2 June 2021

Primary endpoint
15 November 2021

3 August 2022

Quick facts

Lead sponsor	MiCo BioMed Co., Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	218
Start date	2 June 2021
Primary completion	15 November 2021
Estimated completion	3 August 2022
Sites	5 locations across United States

Conditions studied

SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

MiCo BioMed Co., Ltd.

Who can join

18 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test. When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05338762 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MiCo BioMed Co., Ltd.
Last refreshed: 11 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05338762.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing